Domain Therapeutics

Merck Patent Gmbh

Ismet Dorange

Stephan Schann

Stanislas Mayer

Baptiste Manteau

Anne-Laure Blayo

Thomas Catelain

Cédric Genet

The present invention provides novel heterocyclic compounds of the general formula (I), including novel compounds of formula (Ia), and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) or (Ia) and the pharmaceutical compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. The compounds of formula (I) or (Ia) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. The present invention further provides compounds of formula (I) or (Ia) that are modulators of metabotropic glutamate receptors (mGluRs), particularly positive allosteric modulators of mGluRs, and more specifically positive allosteric modulators of mGluR3. 

Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors

Growing community of inventors

Stockholm, Sweden

Ismet Dorange